ONCY vs AMGN vs GILD vs BMY vs MRK

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 3x trailing P/E (21. 7x forward), making it the more compelling value choice. Analysts rate Oncolytics Biotech Inc. (ONCY) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 3x versus Amgen Inc. at 23. 3x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Gilead Sciences, Inc. wins at 0. 12x versus Amgen Inc. 's 5. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +117. 0%, compared to -68. 0% for Oncolytics Biotech Inc. (ONCY). Over 10 years, the gap is even starker: MRK returned +164. 7% versus ONCY's -82. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bristol-Myers Squibb Company (BMY) is the lower-risk stock at 0.

45β versus Oncolytics Biotech Inc. 's 1. 04β — meaning ONCY is approximately 130% more volatile than BMY relative to the S&P 500. On balance sheet safety, Oncolytics Biotech Inc. (ONCY) carries a lower debt/equity ratio of 18% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to 0. 0% for Oncolytics Biotech Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus 0. 0% for Oncolytics Biotech Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 39. 7% versus 0. 0% for ONCY. At the gross margin level — before operating expenses — GILD leads at 78. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Gilead Sciences, Inc. (GILD) is the more undervalued stock at a PEG of 0. 12x versus Amgen Inc. 's 5. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8. 9x forward P/E versus 21. 7x for Merck & Co. , Inc. — 12. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GILD: 23. 4% to $162. 00.

In this comparison, BMY (4.

4% yield), MRK (2. 9% yield), AMGN (2. 9% yield), GILD (2. 4% yield) pay a dividend. ONCY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 2. 9% yield, +164. 7% 10Y return). Both have compounded well over 10 years (MRK: +164. 7%, ONCY: -82. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ONCY is a small-cap quality compounder stock; AMGN is a mid-cap quality compounder stock; GILD is a mid-cap quality compounder stock; BMY is a mid-cap deep-value stock; MRK is a large-cap deep-value stock. AMGN, GILD, BMY, MRK pay a dividend while ONCY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.